Sophie Pierce will be the first person with cystic fibrosis to attempt a 3,200-mile row across the Atlantic Ocean, travelling ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a growing $22.8 billion therapeutics market. Read the IPO report here ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

"Glox to develop precision antibiotics for cystic fibrosis" was originally created and published by Pharmaceutical Technology ...

An international study has identified two types of these so-called dysbioses in cystic fibrosis. They display ... Landmark Study Involving Babies in Ireland Supports Use of Cystic Fibrosis Drug in ...

Bryan Freedman, now defending his client against Blake Lively’s accusations over 'It Ends With Us,' claimed Baldoni’s ...

A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

Virtual choir program founder Ashley Ballou-Bonnema shares her selfless story on living with and advocating for a life with the chronic disease.

Its Respiratory Advisory Committee has recommended funding with high priority for children aged two to five years. The medicine is currently only funded for ages six and up Cystic Fibrosis NZ CEO Lisa ...